精准医学背景下的食管鳞状细胞癌放疗研究进展

doi:10.3760/cma.j.cn371439-20250429-00046

摘要/Abstract

摘要：

食管癌是全球范围内高发的恶性肿瘤之一。约85%的食管癌为食管鳞状细胞癌（ESCC），其发病率与地域分布密切相关，中国等东亚国家及地区尤为突出。随着精准医学时代到来，ESCC的治疗已从单一模式发展为包含手术、化疗、放疗及免疫治疗的多学科综合诊疗体系。放疗作为ESCC的核心治疗手段之一，近年来在技术革新与多学科协同发展推动下取得了显著进步。

关键词: 食道鳞癌, 放射疗法, 综合疗法

Abstract:

Esophageal cancer remains one of the most prevalent malignancies worldwide. About 85% of esophageal cancers are esophageal squamous cell carcinomas （ESCC）， the incidence of which shows significant geographical correlation and exhibits particularly high prevalence in East Asian countries and regions such as China. With the advent of precision medicine， therapeutic strategies for ESCC have evolved from single-modality approaches to a multidisciplinary comprehensive treatment paradigm encompassing surgical resection， systemic chemotherapy， radiotherapy， and immunotherapy. As one of the core treatment methods for ESCC， radiotherapy has made remarkable progress in recent years， driven by technological innovation and the coordinated development of multiple disciplines.

Key words: Esophageal squamous cell carcinoma, Radiotherapy, Combined modality therapy

吕晓岩, 王媛, 王军. 精准医学背景下的食管鳞状细胞癌放疗研究进展[J]. 国际肿瘤学杂志, 2025, 52(5): 268-272.

Lyu Xiaoyan, Wang Yuan, Wang Jun. Advances in precision radiotherapy for esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2025, 52(5): 268-272.

参考文献 40

[1]	Filho AM, Laversanne M, Ferlay J, et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide[J]. Int J Cancer, 2025, 156(7): 1336-1346. DOI: 10.1002/ijc.35278.
[2]	Morgan E, Soerjomataram I, Rumgay H, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020[J]. Gastroenterology, 2022, 163(3): 649-658.e2. DOI: 10.1053/j.gastro.2022.05.054. pmid: 35671803
[3]	中华医学会放射肿瘤治疗学分会, 中国医师协会放射肿瘤治疗医师分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南(2024年版)[J]. 国际肿瘤学杂志, 2025, 52(1): 3-22. DOI: 10.3760/cma.j.cn371439-20250103-00002.
[4]	Tachimori Y, Ozawa S, Fujishiro M, et al. Comprehensive registry of esophageal cancer in Japan, 2006[J]. Esophagus, 2014, 11(1): 21-47. DOI: 10.1007/s10388-013-0393-5.
[5]	Nihei K, Minashi K, Yano T, et al. Final analysis of diagnostic endoscopic resection followed by selective chemoradiotherapy for stage Ⅰ esophageal cancer: JCOG0508[J]. Gastroenterology, 2023, 164(2): 296-299.e2. DOI: 10.1053/j.gastro.2022.10.002.
[6]	Kato K, Ito Y, Nozaki I, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage Ⅰ esophageal squamous cell carcinoma[J]. Gastroenterology, 2021, 161(6): 1878-1886.e2. DOI: 10.1053/j.gastro.2021.08.007. pmid: 34389340
[7]	Sasaki K, Nomura M, Kato K, et al. A phase Ⅲ randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T_1bN₀M₀ esophageal cancer: ARMADILLO trial (JCOG1904)[J]. Jpn J Clin Oncol, 2024, 54(1): 103-107. DOI: 10.1093/jjco/hyad137.
[8]	Eyck BM, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021, 39(18): 1995-2004. DOI: 10.1200/JCO.20.03614.
[9]	Tang H, Wang H, Fang Y, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial[J]. Ann Oncol, 2023, 34(2): 163-172. DOI: 10.1016/j.annonc.2022. 10.508.
[10]	Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2024, 404(10447): 55-66. DOI: 10.1016/S0140-6736(24)00745-1.
[11]	Yang Y, Wang C, Jiang Y, et al. Different radiation dose of neoadjuvant chemoradiation for resectable thoracic esophageal squamous carcinoma: a randomized phase Ⅱ clinical trial[J]. Int J Radiat Oncol Biol Phys, 2023, 117(2): S13. DOI: 10.1016/j.ijrobp.2023. 06.228.
[12]	Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)[J]. Eur J Cancer, 2021, 144: 232-241. DOI: 10. 1016/j.ejca.2020.11.039. pmid: 33373868
[13]	Yang J, Liu C, Zuo Z, et al. Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): a single-arm, bicentric, phase 2 trial[J]. Radiother Oncol, 2025, 206: 110797. DOI: 10.1016/j.radonc.2025.110797.
[14]	Takeuchi H, Ito Y, Machida R, et al. A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage Ⅱ/Ⅲ esophageal squamous cell carcinoma (JCOG0909 study)[J]. Int J Radiat Oncol Biol Phys, 2022, 114(3): 454-462. DOI: 10.1016/j.ijrobp.2022.07.007.
[15]	Katada C, Yokoyama T, Watanabe A, et al. Optimizing organ-preservation strategies through chemotherapy-based selection in esophageal squamous cell carcinoma: results from the CROC multi-institutional phase 2 clinical trial[J]. Int J Radiat Oncol Biol Phys, 2024, 120(5): 1353-1362. DOI: 10.1016/j.ijrobp.2024.06.019.
[16]	Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7): 965-974. DOI: 10.1016/S1470-2045(18)30201-8. pmid: 29861116
[17]	Yang Y, Liu Z, Wong I, et al. Detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: the prospective multicentre preSINO trial[J]. Br J Surg, 2025, 112(2): znaf004. DOI: 10.1093/bjs/znaf004.
[18]	van der Wilk BJ, Eyck BM, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2025, 26(4): 425-436. DOI: 10.1016/S1470-2045(25)00027-0.
[19]	Dr. B. (Bianca) Mostert, Erasmus Medical Center. Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer:SANO-3 study[EB/OL]. [2025-02-13]. https://onderzoekmetmensen.nl/en/trial/53486.
[20]	Hulshof MCCM, Geijsen ED, Rozema T, et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)[J]. J Clin Oncol, 2021, 39(25): 2816-2824. DOI: 10.1200/JCO.20.03697.
[21]	Xu Y, Dong B, Zhu W, et al. A phase Ⅲ multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma[J]. Clin Cancer Res, 2022, 28(9): 1792-1799. DOI: 10.1158/1078-0432.CCR-21-3843.
[22]	You J, Zhu S, Li J, et al. High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial[J]. Int J Radiat Oncol Biol Phys, 2023, 115(5): 1129-1137. DOI: 10.1016/j.ijrobp.2022.11.006.
[23]	Zhang J, Li M, Zhang K, et al. Concurrent chemoradiotherapy of different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: a rando-mized, multicenter, phase Ⅲ clinical trial[J]. Cancer Commun (Lond), 2024, 44(10): 1173-1188. DOI: 10.1002/cac2.12601.
[24]	Xie C, Jing Z, Luo H, et al. Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial[J]. Br J Cancer, 2020, 123(11): 1616-1624. DOI: 10.1038/s41416-020-01054-6.
[25]	Wang R, Ling Y, Chen B, et al. Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase Ⅱ trial[J]. EClinicalMedicine, 2024, 75: 102806. DOI: 10.1016/j.eclinm.2024.102806.
[26]	Shah MA, Bennouna J, Doi T, et al. KEYNOTE-975 study design: a phase Ⅲ study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma[J]. Future Oncol, 2021, 17(10): 1143-1153. DOI: 10.2217/fon-2020-0969.
[27]	Jiangsu HengRui Medicine Co. Ltd. Study of camrelizumab (SHR-1210) in combination with concurrent chemoradiotherapy in locally advanced esophageal cancer[EB/OL]. [2021-09-14]. https://www.smartpatients.com/trials/NCT04426955#:-:text=This%20is%20a%20randomised%2C%20double-blinded%2C%20placebo-controlled%2C%20multi-center%20phase,for%20locally%20advanced%20esophageal%20cancer%20patients%20in%20China.
[28]	Yu R, Wang W, Li T, et al. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma[J]. Future Oncol, 2021, 17(31): 4081-4089. DOI: 10.2217/fon-2021-0632. pmid: 34269067
[29]	Liu Q, Chen J, Lin Y, et al. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2024, 9(1): 45-55. DOI: 10.1016/S2468-1253(23)00316-3.
[30]	Kroese TE, van Laarhoven HWM, Schoppman SF, et al. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a delphi consensus study in Europe[J]. Eur J Cancer, 2023, 185: 28-39. DOI: 10.1016/j.ejca.2023.02.015. pmid: 36947929
[31]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会, 等. 食管癌寡转移放射治疗专家共识(2025年版)[J]. 中华放射医学与防护杂志, 2025, 45(1): 1-17. DOI: 10.3760/cma.j.cn112271-20241014-00399.
[32]	Chen B, Chen W, Cheng Q, et al. Comparison of efficacy and safety of combined chemoimmunotherapy with or without radiation therapy for stage ⅣB esophageal squamous cell carcinoma: a multicenter propensity score matching analysis[J]. Int J Radiat Oncol Biol Phys, 2024, 120(4): 1084-1095. DOI: 10.1016/j.ijrobp.2024.06.008.
[33]	Li J, Wang X, Cao J, et al. Immunochemotherapy plus radiotherapy versus immunochemotherapy alone as first-line treatment for treatment-naïve, advanced esophageal squamous cell carcinoma (AEC-ICR-1st): a multi-center cohort study[J]. Cancer Lett, 2024, 611: 217411. DOI: 10.1016/j.canlet.2024.217411.
[34]	Mian XI, Sun Yat-sen University. Concurrent chemoradiotherapy for stage ⅣB esophageal squamous cell carcinoma (EC-CRT-003) (EC-CRT-003) [Z/OL]. Bethesda: Sun Yat-sen University. [2022-9-20]. https://clinicaltrials.gov/study/NCT05512520#study-record-dates.
[35]	Wen Y, Shanghai Chest Hospital. Radiotherapy combined with immunochemotherapy in metastatic esophageal squamous cell carcinoma[EB/OL]. [2023-08-07]. https://ichgcp.net/clinical-trials-registry/NCT05978193.
[36]	Jin L, Chen Q, Shi A, et al. Deep learning for automated contouring of gross tumor volumes in esophageal cancer[J]. Front Oncol, 2022, 12: 892171. DOI: 10.3389/fonc.2022.892171.
[37]	Wang J, Zhu X, Zeng J, et al. Using clinical and radiomic feature-based machine learning models to predict pathological complete response in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation[J]. Eur Radiol, 2023, 33(12): 8554-8563. DOI: 10.1007/s00330-023-09884-7. pmid: 37439939
[38]	Zhu Y, Yao W, Xu BC, et al. Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive radiomic biomarkers[J]. BMC Cancer, 2021, 21(1): 1167. DOI: 10.1186/s12885-021-08899-x.
[39]	Zhu C, Mohan R, Lin SH, et al. Identifying individualized risk profiles for radiotherapy-induced lymphopenia among patients with esophageal cancer using machine learning[J]. JCO Clin Cancer Inform, 2021, 5: 1044-1053. DOI: 10.1200/CCI.21.00098. pmid: 34665662
[40]	Nonaka T, Kawashiro S, Ishikawa H, et al. Concurrent chemoradiotherapy using proton beams can reduce cardiopulmonary morbidity in esophageal cancer patients: a systematic review[J]. Esophagus, 2023, 20(4): 605-616. DOI: 10.1007/s10388-023-01015-x. pmid: 37328706